| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Dehydronuciferine targets acetylcholinesterase (AChE), an enzyme that hydrolyzes acetylcholine in the synaptic cleft. It inhibits AChE with an IC50 of 25 μg/mL. By inhibiting AChE, it increases acetylcholine levels, potentially enhancing cholinergic neurotransmission.
|
|---|---|
| ln Vitro |
In vitro, Dehydronuciferine acts as an acetylcholinesterase (AChE) inhibitor with an IC50 of 25 μg/mL. It is isolated from the leaves of Nelumbo nucifera. Its activity is characteristic of AChE inhibitors used in research on Alzheimer's disease and other cholinergic disorders.
|
| ln Vivo |
In vivo activity data for Dehydronuciferine are limited. As an AChE inhibitor, it would be expected to improve cholinergic transmission in vivo, potentially benefiting cognitive function. Further in vivo studies are needed to confirm its efficacy and safety.
|
| Enzyme Assay |
In vitro enzyme assays for Dehydronuciferine are conducted to evaluate AChE inhibition using Ellman's method. AChE activity is measured by monitoring the hydrolysis of acetylthiocholine. The compound is incubated with AChE and substrate at varying concentrations, and IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for Dehydronuciferine are performed using neuronal cell lines expressing AChE. Cells are treated with compound concentrations ranging from 0.1 to 100 µg/mL. AChE activity is measured in cell lysates using colorimetric assays. Cell viability is assessed using MTT or CCK-8 assays.
|
| Animal Protocol |
In vivo animal studies for Dehydronuciferine would typically utilize rodent models of cognitive impairment or Alzheimer's disease. The compound is administered orally or intraperitoneally. Cognitive function is assessed using behavioral tests such as the Morris water maze or novel object recognition. AChE activity and acetylcholine levels are measured in brain tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Dehydronuciferine are not well characterized. The compound has a molecular weight of 293.36 and a molecular formula of C19H19NO2. As a lipophilic alkaloid, it is expected to cross the blood-brain barrier. Standard PK studies in rodents would be required.
|
| Toxicity/Toxicokinetics |
Toxicological data for Dehydronuciferine are limited. As a natural product-derived compound, it may have a moderate safety profile. No significant acute toxicity has been reported. The compound is designated for research use only.
|
| References | |
| Additional Infomation |
Dehydronuciferine is an isoquinoline alkaloid. It has been reported that nuciferine exists in lotus (Nelumbo nucifera), and relevant data are available for reference.
Dehydronuciferine is an aporphine alkaloid from Nelumbo nucifera that acts as an acetylcholinesterase (AChE) inhibitor with an IC50 of 25 μg/mL. It has a molecular weight of 293.36 and formula C19H19NO2. It is not clinically approved. |
| Molecular Formula |
C19H19NO2
|
|---|---|
| Molecular Weight |
293.3597
|
| Exact Mass |
293.141
|
| CAS # |
7630-74-2
|
| PubChem CID |
821347
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.193±0.06 g/cm3
|
| Boiling Point |
493.0±45.0 °C at 760 mmHg
|
| Melting Point |
130 - 131 °C
|
| Flash Point |
190.9±17.3 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.664
|
| LogP |
4.37
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
22
|
| Complexity |
401
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
JBGSWIBJAGBGOP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H19NO2/c1-20-9-8-13-11-16(21-2)19(22-3)18-14-7-5-4-6-12(14)10-15(20)17(13)18/h4-7,10-11H,8-9H2,1-3H3
|
| Chemical Name |
15,16-dimethoxy-10-methyl-10-azatetracyclo[7.7.1.02,7.013,17]heptadeca-1(17),2,4,6,8,13,15-heptaene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~340.88 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (8.52 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.52 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4088 mL | 17.0439 mL | 34.0878 mL | |
| 5 mM | 0.6818 mL | 3.4088 mL | 6.8176 mL | |
| 10 mM | 0.3409 mL | 1.7044 mL | 3.4088 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
